Quantcast
Ebola Protein Blocks Bodys Counterattack On Virus

Ebola Protein Blocks Body's Counterattack On Virus

The Mount Sinai Hospital / Mount Sinai School of Medicine Findings provide framework for new drug development efforts One of the human body's first responses to a viral infection is to make and release signaling proteins called interferons,...

Latest Drug Development Stories

2014-08-11 16:28:15

SARASOTA, Fla., Aug. 11, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it filed with the Securities Exchange Commission its Form 10-Q for the second quarter ended June 30, 2014. The company has also announced a clinical and regulatory update. http://photos.prnewswire.com/prnvar/20140811/135143 Second Quarter, 2014: For the three months ended...

2014-08-11 16:28:03

-- FDA Approval of Omidria(TM) Received on May 30, 2014 - SEATTLE, Aug. 11, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014, which include: -- 2Q...

2014-08-11 12:27:41

COLORADO SPRINGS, Colo., Aug. 11, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, signs a binding letter of intent with its existing Michigan partners, increasing Cannabis Science's equity position from 20% to 50.1% in its joint venture in the Michigan medical cannabis and hemp markets, Michigan Green Technologies LLC (MGT). MGT is the leading resource for legislative...

2014-08-05 08:33:27

SOUTH SAN FRANCISCO, Calif., Aug. 5, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2014. For the second quarter of 2014, Rigel reported a net loss of $25.4 million, or $0.29 per share, compared to a net loss of $22.8 million, or $0.26 per share, in the same period of 2013. Weighted average shares outstanding for the second quarters of 2014 and 2013 were 87.5 million and 87.1...

2014-08-01 08:26:12

BEVERLY HILLS, Calif., Aug. 1, 2014 /PRNewswire/ -- Crown Baus Capital Corp. (OTC: CBCA), a global acquisition-based conglomerate targeting five primary industries: high-tech incubation, drug development, entertainment/media, education, and financial services, sees this week's Congressional efforts to amend the Controlled Substances Act to permit medical use of cannabis on a nationwide basis as history in the making. This federal medical cannabis legalization effort in Congress...

2014-07-31 16:28:08

SARASOTA, Fla., July 31, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced today that it has initiated the development of its lead molecule, Anatabine Citrate, in Europe; and that it has selected Quotient Clinical, The Translational Pharmaceutics Company, based in the United Kingdom (UK) to run its early development programs. http://photos.prnewswire.com/prnvar/20140731/132375 The Company expects to file a Clinical Trial Application (CTA) by the end of...

2014-07-29 23:05:06

MarketReportsOnline.com adds "Latest Guidebook for Conducting Pharma Clinical Trials in China: From Regulations to Practice (2014 Edition)" report to its research store. Dallas, Texas (PRWEB) July 29, 2014 This Latest Guidebook for Conducting Pharma Clinical Trials in China: From Regulations to Practice (2014 Edition) not only provided a comprehensive and thorough knowledge of the latest Chinese regulations on clinical trials for imported drug registration but also introduced...

2014-07-29 08:32:54

Phase I Project to Focus on Advanced Molecular Search Models for the Inverse Design Computational Drug Discovery Platform RESEARCH TRIANGLE PARK, N.C., July 29, 2014 /PRNewswire/ -- Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today that it has been awarded a Phase I grant from the National Science Foundation Small Business Innovation Research (NSF SBIR) program. The grant is valued at $150,000. Cloud...

2014-07-29 08:30:24

BEVERLY HILLS, Calif., July 29, 2014 /PRNewswire/ -- Cannabis Capital Corp. (OTCBB: CBCA) is a global acquisition-based conglomerate targeting five primary industries: High-Tech Incubation, Drug Development, Entertainment/Media, Education, and Financial Services. The Editorial Board of the New York Times strongly voiced its opposition to current federal law on cannabis in its Sunday, July 27, 2014 publication writing, "the federal government should repeal the ban on marijuana.......

2014-07-24 16:27:29

BUENA, N.J., July 24, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic drug development and manufacturing company, announced its financial results for the second quarter ended June 30, 2014. http://photos.prnewswire.com/prnvar/20130827/MM70487LOGO Second Quarter 2014 Highlights -- Total revenues of $6.5 million in the second quarter of 2014, an increase of 70% over the same quarter in 2013 -- Total revenues of $13.3 million...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related